After revolutionizing the weight-loss drug market, Novo ... disease and chronic kidney disease, compared with a placebo. Novo Nordisk’s chief rival, Eli Lilly, also released new heart health ...

which is heading for phase 2 trials in cardiomyopathy associated with ATTR amyloidosis, a life-threatening disease affecting the heart and nervous system. Novo Nordisk also gets rights to the ...

Novo Nordisk’sNOVO.B-0.63%decrease; red down pointing triangle once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks ... cardiovascular disease and/or chronic ...

Novo Nordisk on Saturday said its diabetes pill ... become a new treatment option for people living with diabetes and heart disease. The pill lowered the risk of cardiovascular-related death ...

The Food and Drug Administration approved Novo ... events such as heart attacks and strokes. Novo Nordisk is also studying ...

Novo Nordisk’s attempt to gain an approval to ... the risk of cardiovascular events in adults with established heart disease who are obese or overweight. A heart failure nod was expected to ...

Novo Nordisk has reached an agreement to buy Germany’s Cardior Pharmaceuticals for €1.025 billion ($1.1 billion), adding expertise in RNA therapeutics and a heart failure therapy in mid-stage ...

After a regulatory hiccup earlier this month, Novo Nordisk’s heart failure ... of cardiovascular death, heart and stroke in adult patients with CV disease who have obesity or are overweight.

Oct 21 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said ... including cardiovascular death, non-fatal heart attack and stroke, by 14% compared to placebo, meeting the main goal of the ...

Novo Nordisk’s NVO NONOF obesity medication, Wegovy, has been shown to cause more weight loss in women with prevalent heart disease than in men with the same condition. What Happened ...

The FDA's decision means Ozempic can now be used to reduce the risk of kidney disease worsening ... events such as heart attacks and strokes. Novo Nordisk is also studying Wegovy as a potential ...